High-Purity CSF-1R Inhibitor Composition for Selective Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CSF-1R inhibitors face issues such as off-target toxicity, plasma level increases of CSF-1, and impurities that affect pharmaceutical composition stability and efficacy, necessitating the development of highly pure and selective small-molecule CSF-1R inhibitors for treating conditions like solid tumors and tenosynovial giant cell tumor (TGCT).
Innovation Solution
A highly pure compound represented by Formula (I) or its hydrate, essentially free of certain impurities, is developed for use in pharmaceutical compositions, targeting CSF-1R to treat conditions like TGCT, graft versus host disease (GVHD), neurodegenerative diseases, and various cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small-molecule CSF-1R inhibitors are used, then they can penetrate cells and inhibit CSF-1R kinase activity, but they may also inhibit closely related Type III receptor tyrosine kinases (KIT, PDGFRα/β, FLT3) causing off-target toxicity
Solution Approach 1:
The patent applies local quality by designing the inhibitor molecule with specific structural features (substituents at defined positions on the pyrimidine and phenyl rings) that create localized interaction patterns with CSF-1R's binding pocket. This spatially differentiated molecular structure enables selective binding to CSF-1R while excluding off-target kinases, thereby achieving high selectivity without sacrificing inhibitory efficacy.
2Object-affected harmful factors
If antibodies targeting CSF-1R are used, then they are much more specific, but they result in >10,000-fold increases in plasma levels of CSF-1 due to blockade of CSF-1 clearance
Solution Approach 1:
The patent substitutes the mechanical/physical blockade mechanism of antibodies with a small-molecule competitive inhibition mechanism. The small molecule binds to the CSF-1R kinase domain and blocks ATP binding, preventing downstream signaling without interfering with CSF-1 ligand binding or clearance mechanisms. This mechanism substitution resolves the paradox of achieving specificity while avoiding CSF-1 accumulation.
3Ease of manufacture
If impurities are present in the active pharmaceutical ingredient, then formulation may be easier, but they can cause physical and chemical instabilities, reduce shelf life, and lower therapeutic effects
Solution Approach 1:
The patent applies the extraction principle by developing highly selective purification methods that remove trace impurities from the CSF-1R inhibitor. The purification process extracts and eliminates potential destabilizing contaminants while retaining the active compound, thereby ensuring long-term compositional stability and therapeutic efficacy without compromising manufacturability.
4Ease of manufacture
If surgical excision is performed for diffuse-type TGCT, then it is the standard treatment, but it is difficult to perform marginal excision resulting in high recurrence rate
Solution Approach 1:
The patent introduces a pharmacological intermediary (the CSF-1R inhibitor) that mediates therapeutic effect by blocking the CSF-1/CSF-1R signaling pathway essential for TGCT cell proliferation and survival. This intermediary approach complements surgical excision by providing systemic control of disease activity, thereby reducing recurrence rates while maintaining the feasibility of surgical intervention.
Data Source
AI summary
Provided herein, in part, is a compound of Formula (I)or a hydrate thereof, essentially free of one or more impurities, compositions thereof, and methods of use thereof.